For the year ending 2026-01-31, PATH had -$8,039K decrease in cash & cash equivalents over the period. $352,160K in free cash flow.
| Cash Flow | 2026-01-31 | 2025-01-31 | 2024-01-31 | 2023-01-31 |
|---|---|---|---|---|
| Total revenue | 1,610,572 | 1,429,664 | - | - |
| Adjusted cost of revenue-License | 4,343 | 5,818 | - | - |
| Adjusted cost of revenue-Subscription Services | 139,545 | 142,654 | - | - |
| Adjusted cost of revenue-Professional Services And Other | 98,415 | 59,068 | - | - |
| Adjusted sales and marketing | 587,375 | 583,898 | - | - |
| Adjusted research and development | 250,012 | 242,679 | - | - |
| Adjusted general and administrative | 161,131 | 154,965 | - | - |
| Other segment items | 308,955 | 361,393 | - | - |
| Amortization of acquired intangible assets | 8,191 | 6,711 | - | - |
| Interest income | 48,023 | 49,422 | - | - |
| (benefit from) provision for income taxes | -181,702 | -4,406 | - | - |
| Net income (loss) | 282,330 | -73,694 | -89,883 | -328,352 |
| Depreciation and amortization | 16,969 | 17,232 | 22,597 | 18,723 |
| Amortization of deferred contract acquisition costs | 109,362 | 92,089 | 75,471 | 59,826 |
| Reversal of deferred contract acquisition costs and accrued sales commissions, net | - | - | - | 0 |
| Net accretion on marketable securities | 10,236 | 31,778 | 28,246 | 1,782 |
| Abandonment and impairment charges | - | 0 | 0 | 2,881 |
| Stock-based compensation expense | 290,676 | 358,151 | 371,955 | 369,840 |
| Charitable donation of class a common stock | 4,187 | 6,564 | 4,215 | 5,499 |
| Non-cash operating lease expense | 16,976 | 15,899 | 13,047 | 11,675 |
| (benefit from) provision for deferred income taxes | -202,682 | -19,794 | 554 | 861 |
| Credit loss expense (benefit) | 5,735 | - | - | - |
| Other non-cash charges (credits), net | -7,098 | 2,332 | 3,700 | 2,465 |
| Accounts receivable | 25,802 | 22,173 | 64,217 | 123,783 |
| Contract assets | -3,208 | 3,991 | 14,694 | 185 |
| Deferred contract acquisition costs | 116,202 | 89,157 | 118,833 | 118,909 |
| Prepaid expenses and other assets | 3,933 | -7,065 | -4,222 | 59,810 |
| Accounts payable | -21,675 | 27,856 | -5,052 | -1,571 |
| Accrued expenses and other liabilities | 46,697 | 9,235 | 11,804 | -14,954 |
| Accrued compensation and employee benefits | 2,583 | -23,428 | -4,039 | 15,086 |
| Operating lease liabilities, net | -11,652 | -15,527 | -13,590 | -3,307 |
| Deferred revenue | -22,431 | 68,348 | 137,471 | 160,746 |
| Net cash provided by operating activities | 371,208 | 320,565 | 299,082 | -9,981 |
| Purchases of marketable securities | 772,491 | 1,470,355 | 1,485,965 | 388,409 |
| Sales of marketable securities | - | - | 0 | 0 |
| Maturities of marketable securities | 809,247 | 1,475,584 | 1,050,984 | 151,426 |
| Purchases of property and equipment | 19,048 | 14,923 | 7,342 | 23,815 |
| Payments related to business acquisitions, net of cash acquired | 24,821 | 0 | 0 | 29,542 |
| Capitalized software development costs | - | - | 0 | 0 |
| Purchases of investments | - | 35,809 | - | - |
| Other investing, net | 15,353 | 0 | -2,754 | -1,197 |
| Payment of deferred consideration related to business acquisition | - | 5,570 | 5,863 | - |
| Net cash used in investing activities | -22,466 | -45,503 | -439,569 | -289,143 |
| Repurchase of unvested early exercised stock options | - | 0 | 0 | 1,493 |
| Proceeds from initial public offering, net of underwriting discounts and commissions | - | - | 0 | 0 |
| Payments of initial public offering costs | - | - | 0 | 0 |
| Proceeds from issuance of convertible preferred stock | - | - | 0 | 0 |
| Issuance costs related to convertible preferred stock | - | - | 0 | 0 |
| Repurchases of class a common stock | 329,101 | 390,751 | 102,615 | - |
| Proceeds from exercise of stock options | 1,056 | 8,032 | 6,740 | 8,388 |
| Payments of tax withholdings on net settlement of equity awards | 59,061 | 77,930 | 112,067 | 73,095 |
| Proceeds from credit agreement | - | - | - | 0 |
| Net receipts (payments) of tax withholdings on sell-to-cover equity award transactions | - | 99 | -645 | -9,480 |
| Repayment of credit agreement | - | - | - | 0 |
| Proceeds from employee stock purchase plan contributions | 14,859 | 15,605 | 17,555 | 15,011 |
| Payment of deferred loan costs related to senior secured credit facility | - | - | - | 0 |
| Payments of deferred or contingent consideration related to business acquisitions | 128 | - | - | - |
| Net cash used in financing activities | -372,375 | -450,515 | -196,895 | -60,669 |
| Effect of exchange rate changes | 15,594 | -7,029 | -2,621 | -6,811 |
| Net decrease in cash, cash equivalents, and restricted cash | -8,039 | -182,482 | -340,003 | -366,604 |
| Cash, cash equivalents, and restricted cash at beginning of period | 879,634 | 1,062,116 | 1,402,119 | 1,768,723 |
| Cash, cash equivalents, and restricted cash at end of period | 871,595 | 879,634 | 1,062,116 | 1,402,119 |
UiPath, Inc. (PATH)
UiPath, Inc. (PATH)